Accessnewswire·2026-03-19 12:55Core Insights - Woori IO, a subsidiary of OSR Holdings, has signed a mutual non-disclosure agreement with Sinopharm to explore commercial opportunities in China for its noninvasive glucose monitoring technology [1][2] Company Overview - OSR Holdings, Inc. is a healthcare-focused holding company that aims to advance innovative medical technologies through its subsidiaries [5] - Woori IO Co., Ltd. specializes in developing noninvasive biosensing technologies for glucose monitoring and has been recognized for its innovation in this field [6] Market Opportunity - China has over 140 million people living with diabetes, representing one of the largest and fastest-growing diabetes markets globally [3] - The diabetes device market in China is projected to exceed $12 billion by 2032, driven by the increasing adoption of advanced glucose monitoring technologies [3] Strategic Partnership - The NDA with Sinopharm allows Woori IO to evaluate potential regulatory, clinical, and commercial pathways in China, leveraging Sinopharm's extensive distribution network [2][4] - The engagement with Sinopharm highlights the strategic importance of the Chinese market and the potential for future commercialization of Woori IO's technology [4] Future Prospects - Woori IO is receiving interest from various healthcare organizations and distribution partners, indicating strong demand for its noninvasive glucose monitoring solutions [4] - The company plans to pursue strategic partnerships across international markets to advance its development and commercialization strategies [4]